Prestalia Patent Expiration

PRESTALIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6696481 ADHERA Salt of perindopril and pharmaceutical compositions containing it
Apr, 2023

(1 year, 2 months ago)

US7846961 ADHERA α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
Oct, 2029

(5 years from now)



Prestalia is a drug owned by Adhera Therapeutics Inc. It is used for treating high blood pressure. Prestalia uses Amlodipine Besylate; Perindopril Arginine as an active ingredient. Prestalia was launched by Adhera in 2015. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 05, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 21, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient

Market Authorisation Date: 21 January, 2015

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of PRESTALIA before it's drug patent expiration?
More Information on Dosage

PRESTALIA family patents

Family Patents